Pharmaceutical giant Eli Lilly and Company has announced plans to build a $6.5 billion manufacturing facility in Houston and is expected to create more than 4,600 manufacturing and construction jobs. Construction at the city’s Generation Park is slated to begin in 2026 and become fully operational by 2031.
In a Sept. 23 statement, Lilly revealed it will be manufacturing next-generation synthetic medicine active pharmaceutical products at the Houston location—the second of four new U.S. sites that the company will announce this year.
The new plant will concentrate on manufacturing the firm’s small-molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience….